The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. 1/1000 when using colorimetric substrates such as BCIP/NBT - 1/5000 when using chemiluminescent substrates. Note: EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen.
Use at an assay dependent concentration. PubMed: 21791558
FunctionCleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu- -Ala-393' site.
Tissue specificityExpressed in brain, lung and heart. Expressed at very low level in placenta and skeletal muscles.
DomainThe spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix. The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Post-translational modificationsThe precursor is cleaved by a furin endopeptidase.
Cellular localizationSecreted > extracellular space > extracellular matrix.
References for Anti-ADAMTS4 antibody - Carboxyterminal end (ab28285)
This product has been referenced in:
Funck-Brentano T et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One7:e33543 (2012).
Read more (PubMed: 22432033) »
Peluffo MC et al. Systematic analysis of protease gene expression in the rhesus macaque ovulatory follicle: metalloproteinase involvement in follicle rupture. Endocrinology152:3963-74 (2011).
Read more (PubMed: 21791558) »